| Document |
Document Title |
|
WO/2024/112611A1 |
Provided are compounds that may bind a target protein, and result in modification of the target protein. The compounds may further bind a modifier protein. The modifier protein may carry out or enhance the modification of the target prot...
|
|
WO/2024/108670A1 |
Disclosed are an edoxaban key intermediate and a synthesis method therefor. The edoxaban key intermediate is shown as (1) and is prepared by means of an ammonolysis reaction of raw materials. The intermediate can be used for preparing ed...
|
|
WO/2024/107778A1 |
Disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Compounds of formula (I) are useful for treating coronavirus infection via inhibition of the protease Mpro.
|
|
WO/2024/105364A1 |
The present invention relates to compounds of formula (I). The compounds may be used to inhibit Cdc-Like Kinases, and thereby treat cancer, inflammatory disease, neurodegenerative disease, infection, tendinopathy, Duchenne muscular dystr...
|
|
WO/2024/103123A1 |
Described herein are improved methods of making Compound 1 (4S,7S,10aS)-4-((S)-2- mercapto-3-phenylpropanamido)-5-oxooctahydro-7H-pyrido[2,1-b
][1,3]thiazepine-7-carboxylic acid, or Omapatrilat, and purified Omapatrilat obtained from the...
|
|
WO/2024/098273A1 |
An anti-influenza virus phosphate ester compound and a use thereof. The phosphate ester compound is a compound represented by formula (I) below or a hydrate, a solvate, an optical isomer, a polymorph, an isotope derivative or a pharmaceu...
|
|
WO/2024/098735A1 |
The present application belongs to the technical field of organic electroluminescence, and relates to an organic compound, and an organic electroluminescent apparatus and an electronic device using same. The organic compound has a struct...
|
|
WO/2024/099438A1 |
Disclosed in the present invention are compounds as SUMO activating enzyme inhibitors. Particularly, the present invention relates to compounds as represented by general formula (1) and general formula (2) and preparation methods therefo...
|
|
WO/2024/099386A1 |
The present application relates to the field of pharmaceutical chemistry, relates to a fused bicyclic compound, and in particular relates to a compound represented by formula (II), a stereoisomer or a pharmaceutically acceptable salt the...
|
|
WO/2024/099898A1 |
The invention relates to substituted bi- and tricycles of the general formula (I),and the use of the compounds of the present invention as inhibitorsof HSET for the treatment and/or prevention of hyperproliferative diseases and disorders...
|
|
WO/2024/099478A1 |
A selective inhibitor of PI3Kδ, and a free base, isomer, solvate, pharmaceutically acceptable salt and other structural forms thereof. The compounds have significant antagonistic activity on PI3Kδ, and a pharmacokinetic study shows tha...
|
|
WO/2024/097296A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/097172A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
|
|
WO/2024/088189A1 |
The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or disorders related to CDK9 kinase activity.
|
|
WO/2024/088407A1 |
Disclosed are a nitrogen-containing fused ring compound as shown in formula (I), an intermediate thereof, a preparation method therefor and the use thereof. The compound has a DNA polymerase θ inhibitory activity, and can be used for tr...
|
|
WO/2024/090469A1 |
The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of th...
|
|
WO/2024/046471A9 |
The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...
|
|
WO/2024/082959A1 |
The present invention discloses aggregation-induced emission fluorescent compounds with near-infrared (NIR) emission. This fluorescent compound is then encapsulated by polymer matrix to yield nanoaggregates which is confirmed to show an ...
|
|
WO/2024/083980A1 |
The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...
|
|
WO/2024/086252A1 |
The present disclosure relates to compounds of general formula (I) or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, methods for their preparation, the use of said compounds for use as a medicament, and their use in ...
|
|
WO/2024/086634A1 |
The application relates to heterocyclic heteroaromatic macrocyclic ether compounds of the general Formula (I), pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds act as selective inh...
|
|
WO/2024/083223A1 |
The present disclosure relates to macrocyclic compounds and the medical use thereof, the structures of the macrocyclic compounds being represented as formula (I). The present disclosure also relates to a method for preparing the compound...
|
|
WO/2024/082958A1 |
The present invention discloses aggregation-induced emission fluorescent compounds with near-infrared (NIR) emission. The present invention also shows application for imaging-guided phototheranostic with the integration of both photodyna...
|
|
WO/2024/077391A1 |
Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are o...
|
|
WO/2024/076300A1 |
Compounds of the general formula (I) as described and defined herein, in particular compounds of formula (II), methods for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of sa...
|
|
WO/2024/075696A1 |
The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc. A compound represented by formula (1) or a pharma...
|
|
WO/2024/073658A1 |
The subject matter described herein is directed to myelin-promoting compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of admin...
|
|
WO/2024/071398A1 |
The purpose of the present invention is to provide a drug for the prevention and/or treatment of diseases associated with ABHD6, said drug containing a compound having ABHD6 inhibitory activity as an active ingredient. A compound represe...
|
|
WO/2024/072794A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/060966A1 |
The present invention relates to a pan-KRAS inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inflam...
|
|
WO/2024/061298A1 |
The present invention relates to a heterocyclo-substituted methanone derivative and the use thereof. In particular, the present invention provides a solid form of (S)-(3-amino-5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperid
in]-1'-yl)pyr...
|
|
WO/2024/057021A1 |
The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
|
|
WO/2024/059563A1 |
Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.
|
|
WO/2024/055196A1 |
The present invention relates to an acceptor-donor-acceptor (A-D-A) type organic compound and a preparation method therefor. The material has a thermal activation delayed fluorescence property; a monomolecular structure presents a face-t...
|
|
WO/2024/059010A1 |
The present application relates to compounds of Formula (A), as defined herein, and pharmaceutically acceptable salts thereof, as well as processes for preparing compounds of Formula (A), and pharmaceutically acceptable salts thereof. Th...
|
|
WO/2024/059798A1 |
A composite material, comprising one or more thiazolothiazole (TTz) compounds and one or more matrix materials is described herein. In another aspect, a sensor comprising a composite material comprising one or more thiazolothiazole (TTz)...
|
|
WO/2024/059524A1 |
The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
|
WO/2024/054851A1 |
The present disclosure includes, among other things, macrocyclic CFTR modulators of formula I, pharmaceutical compositions, and methods of making and using the same.
|
|
WO/2024/054840A1 |
The present disclosure includes, among other things, compounds of formula I (I) as CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
|
|
WO/2024/051778A1 |
Provided herein are compounds having a Formula II-4, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds in inhibiting PI3K in a cell, or in treati...
|
|
WO/2024/051784A1 |
Provided are a nitrogen-containing heterocyclic compound, a pharmaceutical composition thereof, and use thereof. The structure of the nitrogen-containing heterocyclic compound is represented by formula I. The nitrogen-containing heterocy...
|
|
WO/2024/053350A1 |
The purpose of the present invention is to provide a method for producing an aminoazide compound and a diamine compound in which the formation of undesired diastereomers is inhibited and which has good diastereoselectivity. Provided is a...
|
|
WO/2024/051702A1 |
The present invention relates to a compound used as an inhibitor of a CDK4 kinase and use thereof. Specifically, the compound of the present invention has a structure represented by formula (I), wherein the definitions of each group and ...
|
|
WO/2024/050809A1 |
Provided is a method for the glycosylation modification of proteins and/or polypeptides, belonging to the technical field of medicinal chemistry. Using glycosyl sulfinate as a raw material, a method for the glycosylation modification of ...
|
|
WO/2024/050370A1 |
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2024/049760A1 |
The present disclosure provides, in part, cyclic urea thiazolyl compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.
|
|
WO/2024/046361A1 |
The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or conditions related to the activity of RIPK1 kinase.
|
|
WO/2024/044713A1 |
The present disclosure relates to compounds and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers.
|
|
WO/2024/042961A1 |
Provided is a compound represented by formula (1). In formula (1), Ar11, Ar12, and Ar13 represent a 1,4-phenylene group, a 1,4-naphthylene group, or a divalent aromatic condensed heterocyclic group having two five-membered rings, and at ...
|
|
WO/2024/040190A1 |
Provided are compounds of Formula (I). Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formu...
|
